Takeda restructuring R&D in U.S., Japan

In a new restructuring plan unveiled Friday, Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said it plans to "reduce and concentrate" its R&D in Japan and the U.S.

In a presentation, CMO and CSO Andrew Plump said Takeda's R&D organization will now be a "dual-centered" structure in Japan and Boston, with "lean regional centers" to help manage local studies and regional issues with global studies. He acknowledged a headcount reduction, but declined to say how many jobs would be affected. ...